French connection boosts Inivata lung cancer trial
Inivata, a Cambridge-based leader in liquid biopsy, and the Centre Léon Bérard cancer centre in Lyon, France, have started a randomised phase III clinical trial to evaluate time to appropriate treatment in patients with suspected metastatic lung cancer.
The trial is comparing Inivata’s InVisionFirst®-Lung liquid biopsy test to standard of care tissue biopsy. This is the first interventional study for Inivata’s technology.
The study will enrol some 286 patients across 17 clinical sites in France. The trial will demonstrate if Inivata’s liquid biopsy test could be used in routine clinical practice to reduce the time to appropriate treatment for targeted lung cancer therapies, whilst assessing whether it has the potential to be complementary to tissue profiling for other therapeutic selection.
The primary end point of the study is a reduction in time to treatment of more than 20 per cent in the overall population of patients with suspected metastatic lung cancer. The study will also evaluate clinical outcomes, including progression-free-survival.
Inivata CEO Clive Morris said: “We are committed to continuing to build a highly robust body of evidence around the use of our liquid biopsy tests and are excited to be starting this real-life, interventional study which we believe to be the first of its type in the liquid biopsy field.
“We have already published the strong clinical validation results that underpinned our positive Medicare reimbursement decision, and are proud to be working with high-quality teams around the world to develop a deeper understanding of the impact InVisionFirst-Lung can have on treatment.”
Inivata’s technology is already in global demand. The company has just signed a distribution agreement with IPS Genomix to provide cancer patients and partners in the Middle East and Africa with access to its InVisionFirst®-Lung and InVisionSeq™ liquid biopsy tests.
The agreement will cover the UAE, Qatar, Kuwait, Bahrain, Lebanon, Jordan, Egypt, and the KSA. IPS Genomix will facilitate patient access to Inivata’s tests through both insurers and the private pay market.
IPS Genomix is part of Integrated Pharma Solutions (IPS), which offers diverse and integrated pharmaceutical, diagnostic and precision medicine solutions for patients covering the Middle East and Africa.
Clive Morris said: “The agreement further highlights Inivata’s growing momentum and expands our geographical reach outside our core market of the US.”